FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413378615> ?p ?o ?g. }

• W2413378615 abstract "Abstract The purpose of this work is to present the results of allogeneic stem cell transplantation as therapy for patients diagnosed with acquired aplastic anemia in the Department of Bone Marrow Transplantation of Fundeni Clinical Institute and to elaborate an algorithm of treatment in aplastic anemia starting with the observations obtained from our clinical practice and following the European treatment guidelines in this group of patients. Aplastic Anemia (AA) is a rare hematological disease characterized by pancytopenia and a hypocellular bone marrow. The paradigm of bone marrow failure syndromes, aplastic anemia is a diagnosis of exclusion despite the precision of its diagnosis criteria. Although AA is not a malignant disease, but an autoimmune disorder, the grave consequences of pancytopenia and clonal transformation into acute leukemia make it a potentially fatal condition. The management of AA patients is challenging and necessitates a very well established treatment plan from the diagnosis. We present the treatment algorithm for AA patients with recommendations based on both recent guidelines in the field and on our experience treating AA patients with allogeneic stem cell transplant. Therapeutic procedure algorithm comprises different approaches for different patient populations, age categories and availability of immunosuppression therapy or different types of donors. According to the recent EBMT recommendations the treatment of choice for young patients (younger than 40 years) who have a matched sibling donor is hematopoietic stem cell transplantation (HSCT). For those patients who don’t have a matched sibling donor or are not candidates for HSCT due to older age, the immunosuppression with ATG and cyclosporine is an efficient treatment. The supportive care has an important role and the patients with aplastic anemia should be managed by a multidisciplinary team. For patients older than 40 years, the choice between immunosuppressive therapy (IST) and upfront transplant with HLA identical sibling donor remains a key question. However, the standard approaches for this category of patients is front line immunosuppression with ATG and cyclosporine and if they become refractory to at least one course of IST the allogeneic stem cell transplant using fludarabine-based conditioning is the second-line treatment option. In our institution there were eleven AA patients treated with allogeneic stem cell transplantation from 2009 till 2015. They were all young patients with age between 19 and 42 years old and all had severe acquired aplastic anemia with transfusion dependence. Six cases were transplanted from a matched sibling donor and five patients had undergone an unrelated matched donor transplant. The allogeneic HSCT procedure was done both as front line therapy in the case of three patients and as second treatment choice in the rest of eight patients. Four patients died, three of them due to transplant related toxicity and one patient experienced severe autoimmune reaction with transfusion inefficacy complicated with intracerebral haemorrhage at four months from transplant. In our opinion the most challenging aspect in treating AA patients is choosing the best treatment option taking into account the patient age and performance status, the severity of the disease and the availability of a donor for allogeneic HSCT. Although the treatment strategy must be individualized in every patient case, it is necessary to make a standardization of treatment procedures in AA and to follow the evidence based recommendations available in the management of this rare disease." @default.
• W2413378615 created "2016-06-24" @default.
• W2413378615 creator A5032703918 @default.
• W2413378615 creator A5045516900 @default.
• W2413378615 creator A5059251853 @default.
• W2413378615 creator A5062406734 @default.
• W2413378615 creator A5074481344 @default.
• W2413378615 creator A5076823934 @default.
• W2413378615 creator A5080926058 @default.
• W2413378615 creator A5082402742 @default.
• W2413378615 creator A5084529065 @default.
• W2413378615 creator A5086115685 @default.
• W2413378615 date "2015-05-01" @default.
• W2413378615 modified "2023-09-26" @default.
• W2413378615 title "Updates in acquired aplastic anemia: Can we do more for our patients?" @default.
• W2413378615 cites W1663740507 @default.
• W2413378615 cites W1923634318 @default.
• W2413378615 cites W1965089841 @default.
• W2413378615 cites W1969849446 @default.
• W2413378615 cites W1970972261 @default.
• W2413378615 cites W1971557056 @default.
• W2413378615 cites W1978723377 @default.
• W2413378615 cites W1997774904 @default.
• W2413378615 cites W2014400250 @default.
• W2413378615 cites W2016294085 @default.
• W2413378615 cites W2018493712 @default.
• W2413378615 cites W2025954849 @default.
• W2413378615 cites W2032667154 @default.
• W2413378615 cites W2037713259 @default.
• W2413378615 cites W2037894368 @default.
• W2413378615 cites W2044804132 @default.
• W2413378615 cites W2059786268 @default.
• W2413378615 cites W2071152504 @default.
• W2413378615 cites W2076630716 @default.
• W2413378615 cites W2086905870 @default.
• W2413378615 cites W2089278876 @default.
• W2413378615 cites W2106456757 @default.
• W2413378615 cites W2129219275 @default.
• W2413378615 cites W2130333050 @default.
• W2413378615 cites W2132824197 @default.
• W2413378615 cites W2149753414 @default.
• W2413378615 cites W2164126075 @default.
• W2413378615 cites W2171228629 @default.
• W2413378615 cites W2259993124 @default.
• W2413378615 doi "https://doi.org/10.1515/dch-2015-0001" @default.
• W2413378615 hasPublicationYear "2015" @default.
• W2413378615 type Work @default.
• W2413378615 sameAs 2413378615 @default.
• W2413378615 citedByCount "0" @default.
• W2413378615 crossrefType "journal-article" @default.
• W2413378615 hasAuthorship W2413378615A5032703918 @default.
• W2413378615 hasAuthorship W2413378615A5045516900 @default.
• W2413378615 hasAuthorship W2413378615A5059251853 @default.
• W2413378615 hasAuthorship W2413378615A5062406734 @default.
• W2413378615 hasAuthorship W2413378615A5074481344 @default.
• W2413378615 hasAuthorship W2413378615A5076823934 @default.
• W2413378615 hasAuthorship W2413378615A5080926058 @default.
• W2413378615 hasAuthorship W2413378615A5082402742 @default.
• W2413378615 hasAuthorship W2413378615A5084529065 @default.
• W2413378615 hasAuthorship W2413378615A5086115685 @default.
• W2413378615 hasBestOaLocation W24133786151 @default.
• W2413378615 hasConcept C126322002 @default.
• W2413378615 hasConcept C203014093 @default.
• W2413378615 hasConcept C2778248108 @default.
• W2413378615 hasConcept C2780007613 @default.
• W2413378615 hasConcept C2781440808 @default.
• W2413378615 hasConcept C41008148 @default.
• W2413378615 hasConcept C71924100 @default.
• W2413378615 hasConceptScore W2413378615C126322002 @default.
• W2413378615 hasConceptScore W2413378615C203014093 @default.
• W2413378615 hasConceptScore W2413378615C2778248108 @default.
• W2413378615 hasConceptScore W2413378615C2780007613 @default.
• W2413378615 hasConceptScore W2413378615C2781440808 @default.
• W2413378615 hasConceptScore W2413378615C41008148 @default.
• W2413378615 hasConceptScore W2413378615C71924100 @default.
• W2413378615 hasLocation W24133786151 @default.
• W2413378615 hasOpenAccess W2413378615 @default.
• W2413378615 hasPrimaryLocation W24133786151 @default.
• W2413378615 isParatext "false" @default.
• W2413378615 isRetracted "false" @default.
• W2413378615 magId "2413378615" @default.
• W2413378615 workType "article" @default.